Two Sigma Advisers
EVFM

Two Sigma Advisers’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Two Sigma Advisers’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,041
Closed -$37K – 2668
2020
Q3 		$37K Buy
1,041
+13
+1% +$565 ﹤0.01% 2342
2020
Q2 		$44K Buy
+1,028
New +$69.3K ﹤0.01% 2433
2016
Q2 		– Sell
-150
Closed -$8K – 2241
2016
Q1 		$8K Sell
150
-140
-48% -$10.8K ﹤0.01% 2012
2015
Q4 		$36K Buy
+290
New +$191K ﹤0.01% 1832

Other funds holding EVFM

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TWMP
Taylor Wealth Management Partners Boston, Massachusetts $176M AUM 14.65% 1-Year Est. Return

Two Sigma Advisers's EVFM Position: Q4 2020 in Review

Two Sigma Advisers sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q4 2020, closing a stake of 1,041 shares — an estimated $37K sold.

Two Sigma Advisers first reported a position in EVFM in Q4 2015 and held it in 4 quarters. The position peaked at $44K in Q2 2020. 93 funds tracked by Wall St. Rank hold EVFM as of Q4 2020.

  • Two Sigma Advisers reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Two Sigma Advisers sold 1,041 Evofem Biosciences, Inc. Common Stock shares in Q4 2020, an estimated $37K.
  • Two Sigma Advisers first reported a position in Evofem Biosciences, Inc. Common Stock in Q4 2015 and held it in 4 quarters.
  • Two Sigma Advisers's Evofem Biosciences, Inc. Common Stock position peaked at $44K in Q2 2020.
  • 93 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q4 2020.

Based on Two Sigma Advisers's 13F filing for Q4 2020, filed 16 Feb 2021.